中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 37 Issue 12
Dec.  2021
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2021  >  37(12): 2756-2759

Portal hypertension: Chronic multiple organ failure involving various critical severe diseases

DOI: 10.3969/j.issn.1001-5256.2021.12.002

  • Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu 610041, China

  • Received Date: 2021-08-21
  • Accepted Date: 2021-08-31
  • Published Date: 2021-12-20
    Abstract
  • Globally, the population living with liver cirrhosis is growing. There is the largest number of cirrhosis patients in China throughout the world. Acute-on-chronic liver failure (ACLF) is a clinical syndrome of sudden hepatic decompensations such as variceal bleeding, spontaneous bacterial peritonitis, hepatic encephalopathy and hepatorenal syndrome seen in patients with liver cirrhosis. ACLF leads to poor quality of life and high mortality. Portal hypertension is not only a consequence of the development of cirrhosis, but also a secondary or even superimposed attack to the development of cirrhosis. It is necessary to early reduce intrahepatic resistance by transjugular intrahepatic portosystemic shunt and drugs to improve the prognosis.

     

    • FullText(HTML)
  • loading
    • References(25)
  • [1]
    LIU Z, JIANG Y, YUAN H, et al. The trends in incidence of primary liver cancer caused by specific etiologies: Results from the Global Burden of Disease Study 2016 and implications for liver cancer prevention[J]. J Hepatol, 2019, 70(4): 674-683. DOI: 10.1016/j.jhep.2018.12.001.
    [2]
    D'AMICO G, PASTA L, MORABITO A, et al. Competing risks and prognostic stages of cirrhosis: A 25-year inception cohort study of 494 patients[J]. Aliment Pharmacol Ther, 2014, 39(10): 1180-1193. DOI: 10.1111/apt.12721.
    [3]
    AITHAL GP, PALANIYAPPAN N, CHINA L, et al. Guidelines on the management of ascites in cirrhosis[J]. Gut, 2021, 70(1): 9-29. DOI: 10.1136/gutjnl-2020-321790.
    [4]
    KUMAR R, MEHTA G, JALAN R. Acute-on-chronic liver failure[J]. Clin Med (Lond), 2020, 20(5): 501-504. DOI: 10.7861/clinmed.2020-0631.
    [5]
    TREBICKA J, GU W, IBÁÑEZ-SAMANIEGO L, et al. Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS[J]. J Hepatol, 2020, 73(5): 1082-1091. DOI: 10.1016/j.jhep.2020.04.024.
    [6]
    MANNING C, ELZUBEIR A, ALAM S. The role of pre-emptive transjugular intrahepatic portosystemic shunt in acute variceal bleeding: A literature review[J]. Ther Adv Chronic Dis, 2021, 12: 2040622321995771. DOI: 10.1177/2040622321995771.
    [7]
    GAO B, ZHUGE YZ. Malnutrition in liver cirrhosis: Benefits from improving portal hypertension[J]. J Clin Hepatol, 2021, 37(12): 2767-2769. DOI: 10.3969/j.issn.1001-5256.2021.12.005.

    高波, 诸葛宇征. 肝硬化营养不良——从改善门静脉高压获益[J]. 临床肝胆病杂志, 2021, 37(12): 2767-2769. DOI: 10.3969/j.issn.1001-5256.2021.12.005.
    [8]
    QIAN SJ, WU H. Hepatic encephalopathy: Modern views on the treatment of abnormal portosystemic shunt[J]. J Clin Hepatol, 2021, 37(12): 2774-2777. DOI: 10.3969/j.issn.1001-5256.2021.12.007.

    钱帅杰, 吴浩. 肝性脑病——异常门体分流处理的现代观[J]. 临床肝胆病杂志, 2021, 37(12): 2774-2777. DOI: 10.3969/j.issn.1001-5256.2021.12.007.
    [9]
    YANG LH, YANG JH. Mechanism and treatment of portal-systemic circulatory imbalance in hepatorenal syndrome[J]. J Clin Hepatol, 2021, 37(12): 2770-2773. DOI: 10.3969/j.issn.1001-5256.2021.12.006.

    杨黎宏, 杨晋辉. 肝肾综合征门体循环失衡的机制与治疗[J]. 临床肝胆病杂志, 2021, 37(12): 2770-2773. DOI: 10.3969/j.issn.1001-5256.2021.12.006.
    [10]
    HORHAT A, BUREAU C, THABUT D, et al. Transjugular intrahepatic portosystemic shunt in patients with cirrhosis: Indications and posttransjugular intrahepatic portosystemic shunt complications in 2020[J]. United European Gastroenterol J, 2021, 9(2): 203-208. DOI: 10.1177/2050640620952637.
    [11]
    de FRANCHIS R, Baveno Ⅵ Faculty. Expanding consensus in portal hypertension: Report of the Baveno Ⅵ Consensus Workshop: Stratifying risk and individualizing care for portal hypertension[J]. J Hepatol, 2015, 63(3): 743-752. DOI: 10.1016/j.jhep.2015.05.022.
    [12]
    TRIPATHI D, STANLEY AJ, HAYES PC, et al. U.K. guidelines on the management of variceal haemorrhage in cirrhotic patients[J]. Gut, 2015, 64(11): 1680-1704. DOI: 10.1136/gutjnl-2015-309262.
    [13]
    GARCIA-TSAO G, ABRALDES JG, BERZIGOTTI A, et al. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases[J]. Hepatology, 2017, 65(1): 310-335. DOI: 10.1002/hep.28906.
    [14]
    European Association for the Study of the Liver. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis[J]. J Hepatol, 2018, 69(2): 406-460. DOI: 10.1016/j.jhep.2018.03.024.
    [15]
    RÖSSLE M, SIEGERSTETTER V, OLSCHEWSKI M, et al. How much reduction in portal pressure is necessary to prevent variceal rebleeding? A longitudinal study in 225 patients with transjugular intrahepatic portosystemic shunts[J]. Am J Gastroenterol, 2001, 96(12): 3379-3383. DOI: 10.1111/j.1572-0241.2001.05340.x.
    [16]
    CHEN S, LI X, WEI B, et al. Recurrent variceal bleeding and shunt patency: Prospective randomized controlled trial of transjugular intrahepatic portosystemic shunt alone or combined with coronary vein embolization[J]. Radiology, 2013, 268(3): 900-906. DOI: 10.1148/radiol.13120800.
    [17]
    LI Z, ZHANG CQ. Esophageal and gastric variceal bleeding in liver cirrhosis: Embolization or shunt[J]. J Clin Hepatol, 2021, 37(12): 2764-2766. DOI: 10.3969/j.issn.1001-5256.2021.12.004.

    李振, 张春清. 肝硬化食管胃静脉曲张出血: 堵抑或疏?[J]. 临床肝胆病杂志, 2021, 37(12): 2764-2766. DOI: 10.3969/j.issn.1001-5256.2021.12.004.
    [18]
    GAO JH, WEN SL, TONG H, et al. Inhibition of cyclooxygenase-2 alleviates liver cirrhosis via improvement of the dysfunctional gut-liver axis in rats[J]. Am J Physiol Gastrointest Liver Physiol, 2016, 310(11): g962-g972. DOI: 10.1152/ajpgi.00428.2015.
    [19]
    WEN SL, GAO JH, YANG WJ, et al. Celecoxib attenuates hepatic cirrhosis through inhibition of epithelial-to-mesenchymal transition of hepatocytes[J]. J Gastroenterol Hepatol, 2014, 29(11): 1932-1942. DOI: 10.1111/jgh.12641.
    [20]
    BRUSILOVSKAYA K, KÖNIGSHOFER P, SCHWABL P, et al. Vascular targets for the treatment of portal hypertension[J]. Semin Liver Dis, 2019, 39(4): 483-501. DOI: 10.1055/s-0039-1693115.
    [21]
    TSOCHATZIS EA, SENZOLO M, GERMANI G, et al. Systematic review: Portal vein thrombosis in cirrhosis[J]. Aliment Pharmacol Ther, 2010, 31(3): 366-374. DOI: 10.1111/j.1365-2036.2009.04182.x.
    [22]
    ARROYO V, ANGELI P, MOREAU R, et al. The systemic inflammation hypothesis: Towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis[J]. J Hepatol, 2021, 74(3): 670-685. DOI: 10.1016/j.jhep.2020.11.048.
    [23]
    INTAGLIATA NM, CALDWELL SH, TRIPODI A. Diagnosis, development, and treatment of portal vein thrombosis in patients with and without cirrhosis[J]. Gastroenterology, 2019, 156(6): 1582-1599. e1. DOI: 10.1053/j.gastro.2019.01.265.
    [24]
    BOIKE JR, FLAMM SL. Transjugular intrahepatic portosystemic shunts: Advances and new uses in patients with chronic liver disease[J]. Clin Liver Dis, 2020, 24(3): 373-388. DOI: 10.1016/j.cld.2020.04.007.
    [25]
    TRANAH TH, EDWARDS LA, SCHNABL B, et al. Targeting the gut-liver-immune axis to treat cirrhosis[J]. Gut, 2021, 70(5): 982-994. DOI: 10.1136/gutjnl-2020-320786.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (909) PDF downloads(159) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return